Clinical Trial Sites & Investigators

Export clinical trial sites from ClinicalTrials.gov — one row per site, with the investigator's name, role, phone number and email as published by the sponsor.

No login. No API key. No proxies.

Why one row per site

Every other tool gives you one row per trial, with the sites buried in a nested field — and the leading alternative states plainly that it does not include site contacts or investigator details.

That is the wrong shape for the people who actually need this data. A CRO looking for investigators, a site network scouting partners, a patient recruitment agency, a medical affairs team mapping KOLs — none of them want a study. They want to know who to call.

So this Actor flattens the other way: one row per site, with the contact attached.

Measured on recruiting breast cancer trials, 200 site rows:

	Coverage
Phone number	96 %
Email address	80 %
Coordinates	100 %

Real rows, real institutions — caroli-bosc.p@chu-nice.fr at CHU de Nice, louis.potier@aphp.fr at Bichat-Claude Bernard.

Output

Field	Example
facility	Hadassah Medical Center
siteCity, siteState, siteCountry	Jerusalem, —, Israel
latitude, longitude	31.7683, 35.2137
siteStatus	RECRUITING
contactName	Tanir Michal Eloise, MD
contactRole	CONTACT
contactPhone	+972 2 677 7111
contactEmail	tanir@hadassah.org.il
contactSource	site, central or none
nctId, studyUrl	NCT01234567
briefTitle, overallStatus, phase, studyType
leadSponsor, sponsorClass
conditions, interventions
enrollment, startDate, completionDate
minimumAge, sex, healthyVolunteers
centralContactName, centralContactPhone, centralContactEmail

contactSource tells you where the contact came from. When a site publishes no contact of its own, the study's central contact is used rather than leaving the row unreachable — and the field says so, so you can filter if you only want site-level people.

Input

{
  "condition": "breast cancer",
  "status": ["RECRUITING"],
  "onlyWithContact": true,
  "maxItems": 500
}

Field	Default	Notes
condition	breast cancer	Condition or disease
status	["RECRUITING"]	Nine recruitment statuses
onlyWithContact	true	Keep only rows with a phone or email
maxItems	500	Counts sites, not trials
country	—	Country or city, e.g. France
phase	—	Early Phase 1 through Phase 4
intervention	—	Drug or procedure, e.g. pembrolizumab
sponsor	—	Lead sponsor, e.g. Sanofi
searchTerm	—	Free text across the whole record
maxSitesPerStudy	0	Cap sites per trial; 0 means no cap

maxSitesPerStudy matters more than it looks. Some phase 3 trials register hundreds of sites and would fill your entire export from a single study. Setting it to 2 or 3 spreads the export across many trials — in testing, 60 rows covered 41 different trials instead of 2.

Use cases

• Site selection and feasibility — find centres already recruiting in your indication, with the investigator named.
• Patient recruitment — reach the sites actively enrolling, by city.
• Medical affairs and KOL mapping — see which investigators run which trials, for which sponsor.
• Competitive intelligence — which sponsors are running what, where, at what enrollment.
• CRO business development — a contactable list filtered by indication, phase and country.

Data quality, honestly

This Actor reports exactly what sponsors registered. That means:

• Coverage varies by phase. Academic and early-phase trials usually publish a named investigator with an institutional email. Large industry phase 3 trials often publish a central call centre instead — in testing, a phase 3 slice returned 100 % phone numbers but only 2 % emails.
• Placeholder values exist. Sponsors sometimes register 111-111-1111 or a contact named Site 034. These are in the source record; the Actor does not silently drop them, so filter if they matter to you.
• Registered ≠ current. A site listed as recruiting may have stopped. The registry lags reality.

Personal data

Investigator names, phone numbers and email addresses are personal data. They are published on a public government registry so that patients and researchers can make contact about those trials.

Using them for unrelated commercial outreach is a different purpose, and in the EU or UK that makes you the data controller: you need a lawful basis, you must tell people where their data came from on first contact, and you must honour objections. That obligation is yours, not the tool's.

Notes

• Source: the official ClinicalTrials.gov API v2, public and unauthenticated.
• Requests are paced at roughly one per second out of courtesy to a free public service.
• Not affiliated with ClinicalTrials.gov, the NIH or the NLM.